Glutamine Limitation: GLS1 and ASCT2 Function Blocking Contributes to Osimertinib‐Resistant Lung Cancer Inhibition, Disrupting Energy and Redox Balance. The gene discussed is SLC1A5; the disease is lung carcinoma.